Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference

뉴스 본문을 불러오고 있어요.

Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference | 웨이프 WAPE

Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference

기사 요약

관련 종목

댓글 —